Obermatt
See Similar Stocks →

NeoGenomics

NAQ:NEO · US64049M2098
Health Care Providers & ServicesMedium

360

31
Profit price83
Owner Earnings Yield1
Dividend Yield1
Price/Sales29
EV / Gross Profit46
Price/Book62
Return on Capital20
Cash Return on Capital26
Return on Equity20
EBIT Margin14
Gross Profitability37
Accruals64
Owner Earnings Margin24
Sales growth63
Profit Growth30
Long-Term EPS Growth85
Reinvestment24
Price momentum78
Debt load66
Refinancing85
Debt Payback1
Liquidity11
Analyst ratings40
Opinion Changes50
Price Target Upside66
Market mood68
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

NeoGenomics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
TypePublic Company
ExchangeNASDAQCM
Employees1,500
Websiteneogenomics.com
ISINUS64049M2098
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsHematologyGeneticsOncologyBiotechnologyHealth CareMedicalPharmaceutical

Description

NeoGenomics, Inc. (NeoGenomics) provides a wide range of oncology diagnostic testing and consultative services, including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular exp…

Analysis

Middle-of-the-road

NeoGenomics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
39
2023202420252026

All-time high

75

Jan 2024

All-time low

33

Jan 2025

Average rank

47

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
29
45
41
64
Price/Earnings
10
15
53
20
Price/Book
62
61
54
68
Dividend Yield
1
1
1
1
Value (overall)
20
27
37
51

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare NeoGenomics with its peers
Fulgent Genetics
NMQ:FLGT
4
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Labcorp
NYQ:LH
40
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
AirSculpt Technologies
NMQ:AIRS
26
CountryUSA
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
Quest Diagnostics
NYQ:DGX
35
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Progyny
NSQ:PGNY
92
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
CVS Health
NYQ:CVS
29
CountryUSA
IndustryHealth Care Providers & Services
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →